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Abstract Caveolin-3 (cav-3) is a key structural component of
caveolar membrane in skeletal muscle. Cav-3-enriched light
membrane (CELM) fractions obtained from C2C12 myotubes
contain phospholipase D1 (PLD1) and its major regulators,
RhoA and protein kinase CK (PKCK). All these proteins were
found bound to cav-3. An in vivo assay of PLD activity, which
allows to localize the reaction product in CELMs, indicated that
the enzyme associated to this membrane microdomain was active.
Moreover, bradykinin (BK), thrombin and phorbol 12-myristate
13-acetate induced rapid stimulation of PLD activity in CELMs.
The cav-3-PLD1 complex was not affected by BK treatment,
whereas the agonist induced a marked increase of RhoA
association with cav-3. Furthermore, BK-induced PLD activa-
tion in CELMs was dependent, at least in part, on PKCK.
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1. Introduction
Caveolae are plasma membrane invaginations which are
thought to play a role in many cellular functions including
transcytosis, receptor-mediated uptake, stabilization of lipid
rafts and compartmentalization of a number of signaling
events at the cell surface [1,2].
The principal component of caveolae membranes is caveo-
lin (cav), an integral membrane protein which sequesters sig-
naling molecules in the microdomain by direct interaction
through a speci¢c sca¡olding domain. Three forms of cav
have been identi¢ed and cloned [3]. While caveolin-1 (cav-1)
and caveolin-2 (cav-2) are widely expressed in various tissues,
caveolin-3 (cav-3) has been reported to be muscle-speci¢c [4].
Caveolae are well represented in skeletal muscle where they
have been identi¢ed in the plasma membrane as well as in the
T-tubules [5]. Cav-3 has been shown to interact with the dys-
trophin^glycoprotein complex [4] and the ¢nding that the den-
sity and size of caveolae are modi¢ed in the plasma membrane
from Duchenne muscular dystrophy patients [6] strongly sug-
gests that caveolae play a key role in the organization and
stabilization of the dystrophin cytoskeletal network. A recent
study showed that cav-3 expression is required for myoblast
fusion and myotube formation, further supporting a role for
caveolae in muscle cell physiology [7]. Similarly to cav-1, cav-
3 functions as sca¡old protein, interacting with various pro-
teins containing speci¢c cav-binding domains which recognize
a speci¢c domain located at the N-terminus of the protein
[4].
Phospholipase D (PLD) catalyzes the hydrolysis of the ma-
jor phospholipid, phosphatidylcholine (PtdCho), to generate
phosphatidic acid (PtdOH) and this reaction is implicated in
the regulation of di¡erent cellular processes, such as vesicular
tra⁄cking, cell secretion, proliferation and di¡erentiation
[8,9]. Two mammalian PLDs, PLD1 and PLD2, have been
recently cloned, both widely expressed in many cell types
and tissues [8,9]. Agonist-stimulated PLD activity requires
phosphatidylinositol 4,5-bisphosphate as essential cofactor
and appears to be highly regulated by a complex group of
proteins, including protein kinase C (PKC), monomeric
GTP-binding proteins, such as RhoA and ARF, as well as
protein-tyrosine kinases [8,9].
Previously we demonstrated that in intact C2C12 myoblasts
PLD activity is under the control of ligands acting through G-
protein coupled receptors, such as bradykinin (BK), thrombin
and sphingosine 1-phosphate (SPP) [10,11]. Recently, evidence
has been provided for the localization of PLD activity in
caveolar microdomains in keratinocytes and ¢broblasts [12^
14] suggesting that the enzyme participates in the signaling
cascades initiated from these lipid platforms.
In the present study we report that PLD activity is associ-
ated with cav-3-enriched light membrane (CELM) fractions
from C2C12 myotubes and it is regulated by BK, thrombin
and phorbol 12-myristate 13-acetate (PMA). Moreover, BK
treatment did not a¡ect the immunocomplex PLD-1-cav-3
whereas it increased the level of RhoA, key activator of the
enzyme, associated with cav-3.
2. Materials and methods
2.1. Materials
[3H]Glycerol (30^60 Ci/mmol) was purchased from Du Pont NEN
(Boston, MA, USA), standard lipids from Avanti Polar Lipids
(Alabaster, AL, USA), solvents and silica gel 60 plates for thin-layer
chromatography (TLC) from Merck (Darmstadt, Germany), BK,
thrombin, other chemicals and Protein A- or Protein G-Sepharose
beads were from Sigma (St. Louis, MO, USA). SPP and Go«6976
were from Calbiochem (San Diego, CA, USA). Mouse monoclonal
antibodies against the N-terminal region (3^24) of cav-3 and PKCK
were from Transduction Laboratories (Lexington, KY, USA). Rabbit
polyclonal anti-Rab5 and rabbit polyclonal anti-calnexin were pur-
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 4 8 6 - 1
*Corresponding author. Fax: (39)-55-4222725.
E-mail: biocell@scibio.uni¢.it
Abbreviations: PLD, phospholipase D; cav, caveolin; cav-3, caveolin-
3; CELM, cav-3-enriched light membrane; BK, bradykinin; PMA,
phorbol 12-myristate 13-acetate; PtdCho, phosphatidylcholine;
PtdOH, phosphatidic acid; PtdEtOH, phosphatidylethanol; PtdPro
phosphatidylpropanol; SPP, sphingosine 1-phosphate; MBS, MES
bu¡ered saline; PKC, protein kinase C
FEBS 23620 27-4-00
FEBS 23620FEBS Letters 473 (2000) 10^14
chased from Stressgen Biotech (Victoria, B.C., Canada). PLD1 anti-
peptide was a generous gift of Dr. S. Bourgoin (Ste-Foy, Que., Can-
ada) and was generated as described [15]. Mouse monoclonal anti-
bodies against RhoA and secondary antibodies (horseradish peroxi-
dase-conjugated goat anti-mouse or anti-rabbit immunoglobulin G1)
were from Santa Cruz (Santa Cruz, CA, USA).
2.2. Muscle cell culture
Mouse skeletal C2C12 myoblasts, were obtained from ATCC
(Manassas, VA, USA), maintained as previously described [10] and,
when at 70% con£uent, were induced to di¡erentiate in low mitogen
medium (Dulbecco’s modi¢ed Eagle medium containing 2% horse
serum). Overt di¡erentiation was indicated by the assembly of multi-
nucleated syncytia. The myotubes were used 5^6 days after the cells
were switched to low mitogen media.
2.3. Puri¢cation of cav-3-enriched membranes
CELMs were prepared from myotubes using a discontinuous su-
crose gradient. Con£uent di¡erentiated cells were scraped into MES-
bu¡ered saline (MBS, 25 mM MES, pH 6.5, 0.15 M NaCl) containing
a mixture of protease inhibitors and homogenized with 100 strokes of
Dounce homogenizer. The homogenate was adjusted to 40% sucrose
by 1:1 addition of 80% sucrose prepared in MBS, placed at the bot-
tom of an ultracentrifuge tube and overlaid with two layers of 30 and
5% sucrose in MBS. The gradient was then centrifuged at 200 000Ug
for 18 h using a Beckman SW50 rotor. When control and stimulated
myotubes were compared, equal amounts of protein were fractionated
in the discontinuous gradient. For analysis of the resulting gradient,
0.5 ml fractions were collected from the top of the gradient. The
protein content was quanti¢ed according to the Coomassie Blue pro-
cedure [16].
2.4. Measurement of PLD activity
PLD activity was determined by measuring in sucrose gradient
fractions [3H]phosphatidylpropanol (PtdPro) or [3H]phosphatidyl-
ethanol (PtdEtOH) produced via a PLD-catalyzed transphosphatidy-
lation reaction performed in vivo in the presence of a primary alcohol
such as 1-propanol or ethanol. Serum-starved myotubes were labeled
for 24 h with 5 WCi/ml [3H]glycerol. Basal PLD activity was measured
incubating myotubes for 10 min with 2% 1-propanol. In parallel 2% 2-
propanol was used to quantify unspeci¢c radioactivity which was
subtracted. Agonist-stimulated PLD activity was measured incubating
the cells for 3 min with 2% ethanol prior agonist addition. Cells were
washed twice in ice-cold PBS and scraped in methanol. Lipids were
extracted and [3H]PtdPro or [3H]PtdEtOH was measured after TLC
separation essentially as described [17]. [3H]Phosphatidylalcohol was
normalized to [3H]PtdCho. Analysis of phospholipid species in
[3H]glycerol-labeled cells was determined after lipid extraction of the
indicated sucrose density gradient fractions by TLC separation in a
solvent mixture of chloroform:methanol:acetic acid (90:10:6) and
quanti¢ed as described [10].
2.5. Immunoprecipitation procedures
Single or pooled (2^4) fractions from the sucrose density gradient,
prepared from unstimulated or BK-stimulated myotubes, were diluted
with MBS. The pellet obtained by centrifugation at 200 000Ug, was
resuspended in MBS containing 1% Triton X-100 and incubated over-
night at 4‡C with anti-PLD1 or anti-RhoA or anti-PKCK antibodies.
The immunocomplexes were collected following 2 h incubation with
Protein-A/G-Sepharose beads and washed extensively (¢ve times) with
MBS. The beads were resuspended in 10 Wl of four-fold concentrated
Laemmli electrophoresis bu¡er.
2.6. Western blot analysis
Proteins (5 Wl) from sucrose density gradient fractions or immuno-
complexes from immunoprecipitation experiments were separated by
SDS^PAGE and immunoblotting performed as described [11].
2.7. Presentation of data and statistical analysis
The data were analyzed by Student’s t-test and P6 0.05 was con-
sidered signi¢cant. In immunoblot experiments a blot representative
of at least three similar experiments is presented and to test the stat-
istical signi¢cance, band intensities were measured using NIH Im-
age.
3. Results
To isolate CELMs, myotube lysates were fractionated on a
discontinuous sucrose density gradient and the obtained frac-
tions (0.5 ml) were analyzed for cav-3 immunoreactivity. As it
can be observed from Fig. 1, cav-3 was enriched in fractions 3
and 4 (CELMs) which corresponded to the turbid interphasic
band between 30 and 5% sucrose equilibrium density. Cav-3
was also present in fractions 7 and 8 which sedimented at
higher sucrose density. CELMs excluded intracellular mem-
brane proteins such as calnexin and endosomal and plasma
membrane markers such as Rab5 which were instead enriched
in fractions 8^10 (Fig. 1). Analysis of the protein pro¢le dem-
onstrated that the bulk of protein was present in the high-
density sucrose fractions (Fig. 1). Typically fractions 2^4 con-
tained 2 þ 0.6% of the total protein content. We then exam-
ined whether PLD1 and two of its most important regulators,
RhoA and PKCK, were present in CELMs and were associ-
Fig. 1. Sucrose gradient fractionation of C2C12 myotubes. Cellular
lysates from myotubes were fractionated by £otation in a discontin-
uous sucrose density gradient and the fractions were analyzed for
cav-3, calnexin and Rab5 immunoreactivity and protein concentra-
tion as described in Section 2. Aliquots (5 Wl) of the sucrose gra-
dient fraction were subjected to SDS^PAGE and immunoblotting
with the speci¢c antibodies.
Table 1
E¡ect of mitogens on PLD activity in CELMs
Treatment PLD activity [3H]PtdEtOH/[3H]PtdCho
None 2.2 þ 0.4
BK, 1 WM 3.8 þ 0.2*
PMA, 100 nM 4.8 þ 0.6*
Thrombin, 0.2 U/ml 3.9 þ 0.3*
SPP, 1 WM 2.7 þ 0.3
Con£uent [3H]glycerol labeled myotubes were stimulated with the
indicated concentration of BK, PMA, thrombin or SPP for 1 min
in presence of 2% ethanol. Cells were scraped in MSB and low den-
sity membranes prepared on sucrose gradient as described in Section
2. Fractions 2^4 were pooled and the formation of [3H]PtdEtOH
was measured as described in Section 2. Data are mean þ S.E.M.
of at least three separated experiments performed in duplicate
(*P6 0.05).
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ated with cav-3. Detection of PLD1 by Western analysis was
unsuccessful and required protein immunoprecipitation:
PLD1 was widely distributed throughout the sucrose density
fractions, being however detectable also in CELMs fractions
(2^4). In Fig. 2 the selective immunoprecipitation of cav-3 by
the addition of anti-PLD1 or anti-RhoA or anti-PKCK to
CELMs is shown. Two bands at approximately 26 and 28
kDa, slightly higher than the molecular mass of cav-3 (18
kDa), were also speci¢cally recognized in the immunocom-
plexes with anti-PLD1 by anti-cav-3 antibodies (fractions 2
and 3), suggesting that PLD1, besides interaction with native
cav-3, was associated also with a higher molecular weight
form of the sca¡old protein, possibly resulting from a cova-
lent modi¢cation. Any attempt to detect the PLD2-cav-3 com-
plex in CELMs failed.
The distribution of PLD activity in the sucrose gradient
fractions was then examined utilizing an in vivo assay system,
described in Section 2, based on the PLD-catalyzed transphos-
phatidylation reaction. As shown in Fig. 3, all fractions ex-
hibited PLD activity and two peaks were found corresponding
to fractions 2^4 and fractions 8 and 9. Notably, no signi¢cant
di¡erence in the levels of [3H]glycerol-labeled major phospho-
lipid species between fraction 3 and fraction 8 was observed
(Fig. 3, inset). Remarkably, the enzymatic activity present in
CELMs (fractions 2^4) comprised 37% þ 1.1 (n = 8) of total
cellular PLD activity and it was characterized by the highest
speci¢c activity. The similar observed pattern of distribution
of PLD1-cav-3 immunocomplex and the PLD product
[3H]PtdPro in CELMs suggested that PLD activity was, at
least in part, due to PLD1.
As shown in previous studies [10,11], total PLD activity in
C2C12 myoblasts is rapidly stimulated by mitogens such as
BK, thrombin and SPP. These observations, together with the
results described above, led us to investigate whether also
CELMs-associated PLD activity in myotubes was regulated
by these agonists. Treatment with 1 WM BK, 100 nM PMA
or 0.2 U/ml thrombin for 1 min induced a signi¢cant increase
in enzymatic activity, while SPP was ine¡ective (Table 1).
The possible mechanisms involved in the stimulation of
PLD by BK in CELMs were then investigated. Analysis of
immunoprecipitates obtained from CELMs puri¢ed from un-
Fig. 2. Coimmunoprecipitation of cav-3 with PLD1 or RhoA or PKCK in CELMs from C2C12 myotubes. Single or pooled (2^4) fractions
from the sucrose density gradient were used for immunoprecipitation with polyclonal anti-PLD1 antibodies or mouse monoclonal anti-RhoA
or anti-PKCK antibodies. The immunoprecipitated (IP) complexes were processed as described in Section 2 and analyzed by SDS^PAGE using
8 or 14% polyacrylamide gels. PLD1 and cav-3 were immunodetected (w) using speci¢c antibodies.
Fig. 3. Basal PLD activity distribution in sucrose gradient fractions
from C2C12 myotubes. Fractions from the discontinuous sucrose
density gradient, prepared from unstimulated myotubes were ana-
lyzed for basal PLD activity as described in Section 2. [3H]PtdPro
was normalized to [3H]PtdCho in the TLC. Data are mean þ S.E.M.
of four separated experiments. Inset: Comparison of labeled
PtdCho, phosphatidylserine (PtdSer) and phosphatidylethanolamine
(PtdEtn) levels in sucrose gradient fractions 3 and 8. Phospholipid
(PL) composition was determined as described in Section 2. A rep-
resentative experiment of those from three similar experiments is re-
ported.
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stimulated and BK-stimulated myotubes indicates that the
level of PLD1 associated to cav-3 did not change following
agonist treatment for 1 min (Fig. 4) or 5 min (data not
shown). The possible redistribution in CELMs of the mono-
meric GTP-binding protein RhoA, known to act as direct
activator of PLD1 [8,9,19], was then examined. As shown in
Fig. 5A, addition of anti-PLD1 antibodies to fractions 2^4
resulted in the selective immunoprecipitation of RhoA, indi-
cating that the two proteins directly interact in vivo in
CELMs. Interestingly, association of RhoA with cav-3 in-
creased in BK-treated cells (Fig. 5B). All these ¢ndings sup-
port the possible involvement of RhoA in the BK-induced
PLD regulation. Given that in caveolae obtained from rat
¢broblasts PKCK has been reported to participate in PLD1
regulation [13], we veri¢ed whether it similarly acted in BK-
stimulated PLD localized in muscle CELMs. Notably, treat-
ment of myotubes with 250 nM Go«6976, speci¢c inhibitor of
PKCK in these cells [11,18], 30 min prior to treatment with
BK, signi¢cantly reduced agonist-stimulated PLD activity
(73% þ 8 versus 38% þ 5; n = 3) indicating that CELM-associ-
ated PLD activity is, at least in part, regulated by PKCK.
4. Discussion
Experimental evidence for the localization of PLD in cav-
eolae is limited: in Kim et al. [13] it has been shown that cav-1
coimmunoprecipitates with PLD1 in ¢broblasts and, based on
in vitro experiments, a modulatory role of cav-1 on PLD
activity has been suggested [13]. Similar functional interaction
between PLD and cav-1 in human keratinocytes was reported
also by Czamy et al., although exclusively PLD2 was found in
caveolar microdomains [12,14].
Skeletal muscle caveolae have been proposed to exert a
fundamental role in the organization of cytoskeletal network
and are characterized by the speci¢c expression of cav-3. So
far only nitric oxide synthase (neuronal and inducible forms)
and phosphofructokinase M enzymatic activities have been
found to be bound and regulated by cav-3 in skeletal muscle
[20^22].
Here we provide experimental data for the localization of
PLD1 in myotube CELMs and its association to cav-3. A
signi¢cant amount of basal PLD activity was detectable in
CELMs, however PLD activity and PLD1 distribution in
the low density gradient fractions did not exactly coincide.
Although this ¢nding could be attributable to an at least
partial redistribution of lipids during the membrane puri¢ca-
tion procedure, alternative explanations may exist : PLD1 in
the various gradient fractions could display a di¡erent activa-
tion status as consequence of di¡erential distribution of PLD
cofactor (PIP2) or PLD regulators (PKC isoenzymes, Rho
proteins, ARFs) required to render active otherwise unfunc-
tional PLD1; in addition at present it cannot be ruled out that
PLD2 is also presenting low density membranes and partici-
pates to the bulk of PLD activity detected in CELMs. Inter-
estingly, although the contribution of caveolae to clathrin-in-
dependent endocytosis is unclear [2], the observed PLD
activity in CELMs suggests that the enzyme, known to have
a role in vesicle tra⁄cking, could participate in the physiolog-
ical maintaining of caveolae, which could be exerted by
PtdOH itself or by another PtdOH-derived lipid molecule.
This hypothesis is supported by a recent study in which the
PtdCho-speci¢c PLD/PtdOH phosphohydrolase pathway has
been shown to be active in cav-1-enriched domains in ¢bro-
blasts [23], and proposed to regulate the selective environment
for the actions of enzymes involved in signaling.
Remarkably, CELMs associated-PLD activity in myotubes
appears to be rapidly stimulated by PMA, a direct activator
of PKC and physiological agonists, such as BK and thrombin.
This ¢nding suggests that PLD activity present in caveolar
domains may also play an important role in cell signaling,
modulating the lipid composition and physical factors operat-
ing in these compartments in response to extracellular stimuli.
Cell stimulation with BK did not increase the association of
PLD1 to cav-3 in CELMs suggesting that, upon agonist chal-
lenge, PLD1 did not redistribute to these microdomains and
the enzyme could be regulated in situ either by selective trans-
location of one or more of its regulators or by activation of
resident population of regulators. Intriguingly, a direct inter-
action between PLD1 and RhoA does exist in CELMs and
the observation that BK increased the association of RhoA to
cav-3, supports a role for the recruitment of the cytosolic
monomeric GTPase in the mechanism of PLD stimulation
by BK in this compartment. The relocalization of endogenous
Fig. 4. E¡ect of BK on PLD1 association with cav-3 in CELMs
from C2C12 myotubes. Cav-3-enriched membrane fractions (2^4)
obtained from myotubes stimulated or not with 1 WM BK for 1 min
were incubated with anti-PLD1 antibodies and immunoprecipitation
was performed as described in Section 2. A blot representative of
three similar experiments is presented. Band intensity is reported as
percentage relative to control.
Fig. 5. Association of PLD1 with RhoA (A) and e¡ect of BK on
RhoA-cav-3 immunocomplex (B) in CELMs. A: Immunoprecipita-
tion with anti-PLD1 antibodies was performed as described in Fig.
2 and anti-RhoA antibodies were used to speci¢cally detect the pro-
tein. B: Cav-3-enriched membrane fractions obtained from myo-
tubes stimulated or not with 1 WM BK for 1 min were incubated
with anti-RhoA antibodies and immunoprecipitation experiment
performed as described in Section 2. Cav-3 was detected using
mouse monoclonal anti-cav-3 antibodies. A blot representative of
three similar experiments is presented. Band intensity is reported as
percentage relative to control.
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RhoA induced by platelet-derived growth factor and lyso-
phosphatidic acid in caveolae was reported also in rat-1 ¢bro-
blasts [24].
Moreover, the observations that PMA signi¢cantly in-
creased CELMs-associated PLD activity and that BK-stimu-
lated PLD activity was signi¢cantly reduced by treatment of
myotubes with Go«6976, indicate that in agreement with what
observed in rat ¢broblasts [13] PKCK acts as regulator for
caveolar PLD in C2C12 myotubes.
In conclusion, native PLD was identi¢ed in muscle cav-3-
enriched membranes with a possible role in the physiological
maintaining of caveolar microdomains; the enzymatic activity
appears to be regulated by agonists acting through seven
transmembrane receptors with a mechanism independent
from enzyme recruitment in CELMs. There is growing evi-
dence that altered levels of cav-3 and changes in the num-
ber and size of caveolae take place in the plasma membrane
from muscular dystrophy patients [6,25]; in this connection
it will be worthy to investigate whether any impairment
in PLD membrane microdomain location and signaling oc-
curs in cultured cells from patients a¡ected by this genetic
disease.
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